Deep Vein Thrombosis (DVT) – Medical Student Study Guide

Deep vein thrombosis (DVT) is a core topic in clinical medicine and exam preparation. This guide covers definition, epidemiology, pathophysiology, clinical presentation, diagnosis, management, and high-yield clinical pearls for medical students.

Definition

Deep vein thrombosis (DVT) is the formation of a thrombus (blood clot) within the deep venous system, most commonly in the lower extremities (calf, popliteal, femoral, or iliac veins), but it may also occur in upper extremity or central veins. It is a major component of venous thromboembolism (VTE), which includes both DVT and pulmonary embolism (PE).

Epidemiology

Understanding the epidemiology of DVT helps identify at-risk patients and informs prevention strategies.

DVT is common, with an estimated incidence of venous thromboembolism of approximately 1–2 per 1,000 persons per year in adult populations.
Incidence increases sharply with age; elderly patients have the highest risk.
Hospitalized and post-surgical patients, especially after major orthopedic surgery (hip or knee replacement) and trauma, are at particularly high risk.
There is a modest male predominance in incidence in older age groups.
Recurrent VTE risk is higher in unprovoked DVT, active cancer, and persistent prothrombotic conditions.

Pathophysiology

The pathophysiology of DVT is classically explained by Virchow's triad:

Venous stasis – reduced blood flow promotes clot formation.
Endothelial injury – damage to the vessel wall activates coagulation pathways.
Hypercoagulability – increased tendency of blood to clot.

Venous Stasis

Stasis occurs when venous return is impaired. Common contributors include prolonged immobility (bed rest, long-haul travel), heart failure, paralysis, and venous obstruction (e.g., mass effect, pregnancy-induced compression of pelvic veins).

Endothelial Injury

Endothelial damage exposes subendothelial collagen and tissue factor, triggering platelet adhesion and activation of the coagulation cascade. Causes include surgery, trauma, central venous catheters, and inflammatory conditions affecting vessel walls.

Hypercoagulability

Hypercoagulable states may be inherited (e.g., Factor V Leiden, prothrombin gene mutation, protein C, protein S, or antithrombin deficiency) or acquired (e.g., malignancy, pregnancy, oral contraceptive use, hormone replacement therapy, antiphospholipid syndrome). These states tilt hemostasis toward thrombosis by increasing procoagulant factors, decreasing natural anticoagulants, or impairing fibrinolysis.

Clinical Presentation

DVT can be clinically silent or present with classic but non-specific symptoms. A high index of suspicion is essential.

Typical Symptoms

Unilateral leg swelling – often involving the calf or whole leg.
Leg pain or tenderness – classically in the calf, often worse with standing or walking.
Warmth and erythema over the affected area.
Sensation of heaviness or tightness in the leg.

Physical Examination Findings

Increased circumference of the affected limb compared with the contralateral side.
Pitting edema distal to the thrombus.
Localized tenderness along the course of the deep veins (e.g., calf, popliteal fossa).
Superficial venous dilation or collateral veins in chronic or extensive DVT.

Traditional signs such as Homan’s sign (pain on dorsiflexion of the foot) are non-specific and not recommended as diagnostic tools.

Risk Factors and Clinical Context

Recognizing risk factors is essential for pre-test probability assessment.

Recent surgery (especially orthopedic, pelvic, or major abdominal surgery).
Immobilization (bed rest, plaster casting, long-haul flights > 4–6 hours).
Active cancer or recent chemotherapy.
Pregnancy and postpartum period.
Use of estrogen-containing contraceptives or hormone replacement therapy.
Previous history of VTE.
Inherited thrombophilia (Factor V Leiden, prothrombin G20210A, protein C/S deficiency, antithrombin deficiency).
Obesity, smoking, and advanced age.
Central venous catheters, especially for upper extremity DVT.

Diagnosis

The diagnosis of DVT combines clinical assessment, pre-test probability scoring, D-dimer testing, and imaging, primarily compression ultrasonography.

Clinical Prediction Rules – Wells Score

The Wells score for DVT is a validated tool to estimate pre-test probability. Points are assigned based on clinical features and risk factors (e.g., active cancer, paralysis or immobilization, recent bedridden status, localized tenderness, entire leg swelling, calf swelling > 3 cm, pitting edema confined to symptomatic leg, collateral superficial veins, previous DVT). One point is subtracted if an alternative diagnosis is at least as likely as DVT.

Typical category cutoffs:

Low probability: ≤0
Moderate probability: 1–2
High probability: ≥3

Some versions use a two-level model: ≤1 "unlikely" vs ≥2 "likely". The Wells score guides the need for D-dimer testing and imaging.

D-dimer

D-dimer is a fibrin degradation product elevated in active clot formation and breakdown. It has:

High sensitivity for DVT in low to intermediate pre-test probability patients.
Low specificity – elevated in infection, inflammation, recent surgery, pregnancy, malignancy, and in older adults.

In patients with low clinical probability, a negative high-sensitivity D-dimer can effectively rule out DVT without imaging. Age-adjusted D-dimer cutoffs are often used in older patients (e.g., age × 10 µg/L for patients > 50 years, depending on assay units).

Imaging

Compression Ultrasonography

Compression venous ultrasonography with Doppler is the first-line imaging modality for suspected DVT.

Loss of compressibility of the vein by the probe is the key diagnostic finding.
Used to assess the femoral and popliteal veins and often extended to proximal iliac segments and calf veins depending on protocol.
Sensitivity and specificity are high for proximal lower-extremity DVT; sensitivity is lower for isolated distal (calf) DVT.

Other Imaging Modalities

CT or MR venography – considered when ultrasound is inconclusive, in obese patients, or for pelvic/iliac vein thrombosis.
Conventional contrast venography – historical gold standard but now rarely used due to invasiveness.
Upper extremity DVT – duplex ultrasonography is also first-line.

Laboratory and Thrombophilia Workup

Routine labs (CBC, renal function, liver function) are used to guide therapy and evaluate bleeding risk. Thrombophilia testing is not routinely indicated for all patients and is reserved for selected cases, such as young patients with unprovoked DVT, recurrent events, or strong family history. Testing should generally be deferred until after the acute phase and after anticoagulation has been stopped for an appropriate interval to avoid false results.

Management

Management aims to prevent thrombus extension, reduce risk of pulmonary embolism, relieve symptoms, and prevent long-term complications like post-thrombotic syndrome.

General Principles

Confirm diagnosis (or high clinical suspicion in limited situations) before initiating long-term therapy.
Assess hemodynamic stability, PE risk, bleeding risk, comorbidities, and patient preferences.
Most patients with DVT are treated with systemic anticoagulation.
Duration of therapy depends on whether the DVT is provoked or unprovoked and on bleeding risk.

Initial Anticoagulation (First Hours to Days)

Initial treatment options include:

Direct oral anticoagulants (DOACs) (also called NOACs): rivaroxaban, apixaban, edoxaban, dabigatran.
Low molecular weight heparin (LMWH): e.g., enoxaparin.
Unfractionated heparin (UFH): intravenous infusion, especially in patients with high bleeding risk, severe renal impairment, or hemodynamic instability.

Common Regimens

Rivaroxaban: 15 mg orally twice daily for 21 days, then 20 mg once daily (dose adjust for renal function as per guideline).
Apixaban: 10 mg orally twice daily for 7 days, then 5 mg twice daily; for extended prophylaxis, 2.5 mg twice daily may be used after 6 months in some patients.
Dabigatran or edoxaban: require initial 5–10 days of parenteral anticoagulation (e.g., LMWH) before switching to oral therapy.
LMWH (e.g., enoxaparin): typically 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg once daily (adjust in renal impairment and obesity according to local protocols).
UFH: weight-based intravenous bolus followed by continuous infusion with activated partial thromboplastin time (aPTT) monitoring.

Vitamin K Antagonists (e.g., Warfarin)

Warfarin is an alternative in settings where DOACs are contraindicated, unavailable, or in certain conditions (e.g., mechanical heart valves, severe kidney disease, antiphospholipid syndrome):

Requires overlap with parenteral anticoagulation (LMWH or UFH) for at least 5 days and until the international normalized ratio (INR) is within the therapeutic range (usually 2.0–3.0).
Requires frequent INR monitoring and dose adjustments.

Duration of Anticoagulation

Typical durations (actual decisions individualized based on guideline recommendations and patient factors):

Provoked DVT with transient risk factor (e.g., surgery, trauma, short-term immobilization): usually 3 months of anticoagulation.
Unprovoked DVT (no transient risk factor): at least 3 months; extended or indefinite therapy considered depending on recurrence risk vs bleeding risk.
Active cancer-associated DVT: often at least 3–6 months and continued while cancer is active or under treatment, using LMWH or DOACs depending on current guidelines and patient-specific issues.

Special Situations

Massive or Extensive DVT

Iliofemoral DVT or phlegmasia cerulea dolens (massive DVT with venous congestion and limb ischemia) may require urgent interventions such as catheter-directed thrombolysis, mechanical thrombectomy, or surgical thrombectomy in selected patients.
Systemic thrombolysis is rarely used for DVT alone, more commonly for massive PE with hemodynamic compromise.

Inferior Vena Cava (IVC) Filters

IVC filters are considered when anticoagulation is contraindicated (e.g., active major bleeding) or in rare cases of recurrent VTE despite adequate anticoagulation. Whenever possible, filters should be retrieved once the contraindication is resolved.

Adjunctive Measures

Early ambulation is generally encouraged rather than strict bed rest once anticoagulation is started and the patient is stable.
Graduated compression stockings may be used in some patients to reduce symptoms; evidence for prevention of post-thrombotic syndrome is mixed and recommendations vary.
Analgesia, leg elevation, and supportive care for pain and edema.

Complications

Pulmonary Embolism (PE)

The most serious acute complication of DVT is pulmonary embolism, which occurs when a portion of the thrombus embolizes to the pulmonary arterial circulation. PE can range from asymptomatic to life-threatening and is a major reason for prompt diagnosis and treatment of DVT.

Post-thrombotic Syndrome (PTS)

Post-thrombotic syndrome is a chronic complication due to damage to venous valves and persistent venous obstruction, leading to chronic venous insufficiency.

Symptoms: chronic leg swelling, pain, heaviness, cramps, pruritus.
Signs: skin hyperpigmentation, venous ectasia, lipodermatosclerosis, venous ulcers.
Prevention: adequate anticoagulation, early mobilization; role of compression stockings is variable by guideline and emerging evidence.

Prevention (Prophylaxis)

Preventing DVT, especially in high-risk settings, is a major public health and hospital safety priority.

Pharmacologic Prophylaxis

LMWH in prophylactic doses (e.g., enoxaparin 40 mg subcutaneously once daily) for high-risk hospitalized medical or surgical patients.
Low-dose UFH (e.g., 5000 units subcutaneously every 8–12 hours) in selected patients.
DOACs for prophylaxis in some high-risk surgical patients (e.g., after hip or knee replacement) according to guideline recommendations.

Mechanical Prophylaxis

Intermittent pneumatic compression devices or graduated compression stockings in patients at high bleeding risk or as adjuncts to pharmacologic prophylaxis.
Encourage early mobilization and leg exercises in hospitalized patients.

Key Clinical Pearls for Exams and Practice

DVT and PE together constitute venous thromboembolism (VTE); always consider PE in a patient with DVT and new cardiorespiratory symptoms.
Use a validated clinical prediction rule (e.g., Wells score) as the first step to estimate pre-test probability in suspected DVT.
In low clinical probability patients, a normal high-sensitivity D-dimer effectively rules out DVT and avoids unnecessary imaging.
Compression ultrasonography is the diagnostic imaging of choice for suspected lower-extremity DVT.
DOACs are first-line agents for most patients with DVT due to ease of use and predictable pharmacokinetics, unless contraindicated.
At least 3 months of anticoagulation is standard for a first episode of provoked DVT; longer or indefinite therapy may be indicated for unprovoked DVT or persistent risk factors.
Thrombophilia testing is not required for all patients and should be reserved for selected cases; testing must be timed appropriately relative to anticoagulation.
IVC filters are reserved for patients with acute DVT who cannot receive anticoagulation or have recurrent VTE despite adequate therapy.
Post-thrombotic syndrome is a common chronic complication; counsel patients regarding long-term symptoms and the importance of adherence to therapy.
For exams, remember Virchow’s triad (stasis, endothelial injury, hypercoagulability) as the foundational concept for DVT pathogenesis.

Summary

Deep vein thrombosis is a common and potentially serious condition that medical students must understand thoroughly. Early recognition using clinical prediction rules, appropriate use of D-dimer and imaging, and timely initiation of anticoagulation are central to effective management. Long-term care includes individualizing the duration of therapy, preventing complications like PE and post-thrombotic syndrome, and addressing modifiable risk factors.